COMMUNIQUÉS West-GlobeNewswire
-
La Croix-Rouge canadienne et Walmart Canada donnent le coup d’envoi à la campagne de financement annuelle
25/06/2026 -
Canadian Red Cross and Walmart Canada launch annual giving campaign
25/06/2026 -
Wandercraft Names National Seating & Mobility the Exclusive CRT Distribution Partner for Eve™ Personal Exoskeleton
25/06/2026 -
Survey Exposes a Crisis of Avoidance in Family Caregiving
25/06/2026 -
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment
25/06/2026 -
New PerfectServe Research: 85% of Healthcare Leaders Want to Switch Their Contact Center Vendors, But Most Feel Trapped
25/06/2026 -
The LaVie Institute Introduces Less-Invasive Breast Augmentation Technique with Rapid Recovery
25/06/2026 -
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
25/06/2026 -
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
25/06/2026 -
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practice
25/06/2026 -
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
25/06/2026 -
AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
25/06/2026 -
DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
25/06/2026 -
Young workers willing to make career trade-offs for jobs with pensions: new research from HOOPP and Abacus Data
25/06/2026 -
Un nouveau projet de l’ACE pour soutenir les ergothérapeutes diplômés à l’étranger au Canada
25/06/2026 -
BrewDog Inverurie Reopens with New Community Champions Model
25/06/2026 -
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
25/06/2026 -
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
25/06/2026 -
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
25/06/2026
Pages